Truvada®

DRUG3 trials

Sponsors

Groupe d'Etude sur le Risque d'Exposition des Soignants aux Agents Infectieux, Merck Sharp & Dohme LLC, Viriom

Conditions

HIV InfectionsHIV-1-infection

Phase 1

Comparative Study of PK and BE of VM-1500FDC (Fixed-dose Combination) and Elpida® With Truvada® сo-administrated 1 Daily Fasting in Healthy Subjects

CompletedNCT03706924

ViriomHIV-1-infection

Start: 2018-06-01End: 2018-10-12Updated: 2018-10-30

Phase 2

A Dose-Ranging Study to Compare Doravirine (MK-1439) Plus TRUVADA® Versus Efavirenz Plus TRUVADA® in Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-1439-007)

CompletedNCT01632345

Merck Sharp & Dohme LLCHIV Infections

Start: 2012-10-12End: 2016-03-21Updated: 2019-07-18

Phase 3

Safety Study of Isentress® + Truvada® in Post-exposure Treatment of HIV Infection

CompletedNCT01114425

Groupe d'Etude sur le Risque d'Exposition des Soignants aux Agents InfectieuxHIV Infections

Start: 2010-11-01End: 2012-12-01Updated: 2017-02-23

Related Papers

Once-daily Doravirine for Initial Treatment of Adults Living With Human Immunodeficiency Virus–1: An Integrated Safety Analysis

Clinical Infectious Diseases2019-05-2212 citations

543. An Integrated Safety Analysis Comparing Once-Daily Doravirine (DOR) to Darunavir+Ritonavir (DRV+r) and Efavirenz (EFV) in HIV-1-Infected, Antiretroviral Therapy (ART)-Naïve Adults

Open Forum Infectious Diseases2018-11-011 citations

Doravirine dose Selection and 96-Week Safety and Efficacy versus Efavirenz in Antiretroviral Therapy-Naive Adults with HIV-1 Infection in a Phase IIb Trial

Antiviral Therapy2018-08-0124 citations

Doravirine 100 mg Dose Selected for Subsequent Studies Based on Exposure--Response Analysis

MD Conference Express2014-11-01